Aevi Genomic Medicine — Medgenics — Corporate Update (August 2016)
23 slides from Aevi Genomic Medicine's corporate update, Aug 4, 2016
Slide 1: Mid-Year Review and Business Update
Mid - Year Review and Business Update August 4, 2016
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance, clinical results,
Slide 3: Agenda
Agenda 3 • Mid - Year Summary • Genomic Medicine Approach • Anti - LIGHT Program Overview • Financials & Milestones
Slide 4: Mid Year Summary
Mid Year - Summary 4 ; NFC – 1 Programs Advancing Rapidly – mGlurR + ADHD • Record response and recruitment to phenotype/genotype study (1,000 Patients) • Confirmation of mGluR + prevalence rate of 25% • Enrolment initiating in June with data expected in 2H2016 • US market opportunity of $2 – 3B – 2
Slide 5: Development Pipeline
Development Pipeline 5 Preclinical Phase 1 Phase 2 Phase 3 NFC - 1 mGluR+ ADHD (adolescent, age 12 - 17 ) mGluR+ ADHD (pediatric, age 6 - 12 ) * 22q Deletion Syndrome ** Anti - LIGHT Severe Pediatric Onset IBD TARGT CNS Preclinical POC * Initiate Phase 3, H1 2017 ** Phase 1/2 expected to initiate in
Slide 6: Genomic Medicine Approach
Genomic Medicine Approach medgenics
Slide 7: Genetic Influence in Pediatric Disorders
Genetic Influence in Pediatric Disorders E arly Onset Disease: ; Distinct genetically driven ; Severe burden of illness ; Aggressive progression ; Less responsive to standard of care 7
Slide 8: CAG / CHOP Capabilities
CAG / CHOP Capabilities CAG’s pediatric biobank contains a high percentage of rare genetic variants Datasets (Genomics EMR) ; Over 75K pediatric and 150K related adult patients GWAS genotyped with associated longitudinal EMR since 2006 Data Analytics ; End to end internal Next - Gen sequencing capab
Slide 9: Medgenics Collaboration Capabilities
• Genetic Discovery and Research • BioBank • Computational Biology CHOP/CAG • In - silico search • Animal Models • Genetically predisposed patient populations Translational Medicine • Development • Regulatory • Manufacturing • BD&L • Commercialization Medgenics Collaboration Capabilities 9
Slide 10: Benefits of Genomic Guided Drug Development
Benefits of Genomic Guided Drug Development Higher Value Medicines Improved response rates Smaller, faster, clinical trials Increased probability of regulatory success Targeted launch Potential label expansion in adjacent genetic diseases G enomic biomarkers improve overall program outcomes 10
Slide 11: Anti-LIGHT mAb Program
Anti-LIGHT mAb Program medgenics
Slide 12: Anti-LIGHT mAb Overview
Anti - LIGHT mAb Overview ; First - in - Class Biologic from Kyowa Hakko Kirin – Initial Development in Severe Pediatric Onset IBD – Phase 2 Ready Antibody – Strong Regulatory Exclusivity and Robust Intellectual Property Portfolio – High Value Commercial Opportunity with Potential for Indication Exp
Slide 13: Deal Terms
Deal Terms ; MDGN to: – Requalify KHK clinical supplies – Conduct signal finding study (~$2M) – Exercise option to license on positive data (low single - digit millions USD) ; Following option exercise, KHK elects either: – Partnership • “Co - Development/Co - Commercialization ” – Parties share sal
Slide 14: CAG / CHOP Discovery: Genetic Link to Pediatric Onset IBD
CAG / CHOP Discovery: Genetic Link to Pediatric Onset IBD 14 Key Points ; Established importance of the DcR3 gene in pediatric IBD ; Loss of function of DcR3 correlates with severity ; Prevalence between 10 - 15% Nature Genetics VOLUME 40 | NUMBER 10 | OCTOBER 2008
Slide 15: Rationale for Anti-LIGHT Approach
Rationale for Anti - LIGHT Approach ; DcR3 is strongly linked to Severe Pediatric Onset IBD 1 ; Initial strategy to augment DcR3 – Very short half life – Toxicity reported with previous DcR3 analog ; “Rational Search” based on biological pathway – LIGHT overexpressed in IBD – DcR3 LOF increases LIGH
Slide 16: Human Biomarker Study Supports Role of LIGHT in IBD
Human Biomarker Study Supports Role of LIGHT in IBD 16 Single center non - interventional biomarker study* 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Normal (n=26) Ulcerative Colitis (n=27) Crohn's Disease (n=28) LIGHT mRNA Fold Increase vs Normal *Data on file
Slide 17: Severe Pediatric Onset IBD: Top Down Treatment Paradigm
Severe Pediatric Onset IBD: “Top Down” Treatment Paradigm 17 1 Altwegg & Vincent (2014) TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease. Mediators of Inflammation. doi:10.1155/2014/172821 Treatment Objectives : ; Induce remission with anti - TNFα immediately s
Slide 18: Rapid Development Pathway to Approval
Rapid Development Pathway to Approval 18 Severe Pediatric Onset IBD POC Trial Anticipated Phase 1b design: ; Single center (CHOP) ; N = up to 12 patients ; Duration 8 – 12 weeks ; Ascending dose Endpoints: ; Endoscopic Evaluation, Pediatric Crohn’s Disease Activity Index (PCDAI), Safety Estimated Co
Slide 19: Severe Pediatric Onset IBD: Anti-LIGHT Opportunity
Severe Pediatric Onset IBD: Anti - LIGHT Opportunity (US Pop.) 19 1 Kappleman et al. (2007) Clin Gastro Hepat 2 Oliva - Hemker (2015) J Pedtr 3 Remicade Monograph 4 Altwegg - Vincent (2014) Mediators of Inflamm Initial Target: ; anti - TNFα failure with DcR3 Loss of Function ; 2,000 – 3,000 IBD pati
Slide 20: Financials & Milestones
Financials & Milestones medgenics
Slide 21: Q2 2016 Financial Update
Q2 2016 Financial Update ; Gross and net R&D expenses for the 2 nd Quarter were $8.7M increasing from $4.5M and $3.0M for the same period in 2015 – Primarily due to increased spend on NFC - 1 program and CHOP collaboration ; G&A expenses for the 2 nd Quarter were $2.9M decreasing from $3.9M for the
Slide 22: Upcoming Milestones
Upcoming Milestones *Pending final CHOP approval 22 R&D Programs Timing NFC - 1 Complete enrollment in phenotype / genotype study ✓ Initiate enrollment in Phase 2/3 mGluR+ ADHD Adolescent Trial ✓ Top line data H2 16 Initiate enrollment in Phase 1/2 22q Deletion Syndrome Trial* Q3 16 Initial open - l
Slide 23: medgenics
medgenics